The estimated Net Worth of William C Denby is at least $83.7 Tysiąc dollars as of 24 May 2019. William Denby owns over 6,250 units of Adamis Pharmaceuticals Corp stock worth over $83,738 and over the last 10 years William sold ADMP stock worth over $0.
William has made over 2 trades of the Adamis Pharmaceuticals Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently William bought 6,250 units of ADMP stock worth $10,000 on 24 May 2019.
The largest trade William's ever made was buying 6,250 units of Adamis Pharmaceuticals Corp stock on 24 May 2019 worth over $10,000. On average, William trades about 875 units every 173 days since 2014. As of 24 May 2019 William still owns at least 108,750 units of Adamis Pharmaceuticals Corp stock.
You can see the complete history of William Denby stock trades at the bottom of the page.
William's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130.
Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over $2,051,720 worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth $188,843 . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho..., Dennis J Phd Carlo oraz David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of $12,919. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth $192,500.
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include: